New drug duo aims to fight cancer without harsh chemo

NCT ID NCT04268277

Summary

This study tested a combination of two immunotherapy drugs, pembrolizumab and rituximab, for adults with marginal zone lymphoma who needed treatment. The goal was to see if this chemotherapy-free approach could control the cancer as well as standard treatments that include chemotherapy, but with fewer side effects. The trial was a Phase 2 study that enrolled 22 patients but was later terminated.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brüderkrankenhaus St. Josef, Klinik für Hämatologie und Onkologie

    Paderborn, 33098, Germany

  • Charité Universitätsmedizin Berlin; Hämatologie - Onkologie - Tumorimmunologie

    Berlin, 12200, Germany

  • Gemeinschaftspraxis Dr. med. Johannes Mohm, Dr. med. Gabriele Prange-Krex

    Dresden, 01307, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, 48149, Germany

  • Kliniken Maria Hilf GmbH; Klinik für Hämatologie, Onkologie und Gastroenterologie

    Mönchengladbach, 41063, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

    Chemnitz, 09116, Germany

  • Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin, Onkologie und Hämatologie

    Oldenburg, 26133, Germany

  • Klinikum Passau, II. Medizinische Klinik - Hämatologie, Onkologie und Palliativmedizin

    Passau, 94032, Germany

  • Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Innere Medizin III

    München, 81675, Germany

  • RoMed Klinikum Rosenheim, Med. Klinik II / OTK

    Rosenheim, 83002, Germany

  • Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin

    Stuttgart, 70376, Germany

  • Universitätsklinikum Ulm; Klinik für Innere Medizin Innere Medizin III

    Ulm, Baden-Wurttemberg, 89081, Germany

Conditions

Explore the condition pages connected to this study.